Q5159 Injection, denosumab-dssb, 1 milligrams
Also known as: denosumab biosimilar, RANKL inhibitor, bone-modifying therapy
Injection of denosumab-dssb (Rocakla), a biosimilar to denosumab, administered at 1 milligram per dose.
In Plain Language
bone health injection; osteoporosis treatment; fracture prevention
Clinical Context
Used for giant cell tumors of bone and osteoporosis prevention. Subcutaneous injection inhibiting receptor activator of RANKL protein.
RVU Information
CPT Q5159 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q5159?
CPT Q5159 (Injection, denosumab-dssb, 1 milligrams) is a Q Codes code. Injection of denosumab-dssb (Rocakla), a biosimilar to denosumab, administered at 1 milligram per dose.
Is Q5159 covered by insurance?
Q5159 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for giant cell tumors of bone and osteoporosis prevention. Subcutaneous injection inhibiting receptor activator of RANKL protein.
When is CPT Q5159 used?
Used for giant cell tumors of bone and osteoporosis prevention. Subcutaneous injection inhibiting receptor activator of RANKL protein.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.